• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·RMD
Held by 3 Gurus
Share

ResMed Inc. Stocks

$ 222Last Updated 25.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 32.20B

$ 222
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.1%

Change

+0.01%

Fund

Bridgewater Associates

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Steven Cohen

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

Point72 Asset Management, L.P.

Manager
Fund
Portfolio Weight (%)
Change
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.1%+0.01%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%
Steven CohenPoint72 Asset Management, L.P.0.0%-0.00%

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of RMD is 255 and suggests 14.8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.09.2026 08:00

Agent-Based AI Could Help Micron Overtake Nvidia: What Analysts Expect from the Company's Report

29.09.2026 04:30

AMD will acquire the startup founded by the "godmother of AI" for $8 billion. This will help it compete with Nvidia

29.09.2026 03:02

Gold experienced its sharpest sell-off in three months due to a surge in Treasury yields

29.09.2026 02:09

SpaceX completed Starship's first orbital flight ahead of schedule. Its stock price fell 2%.

29.09.2026 01:20

Regulator Postpones Approval of Long-Awaited Boeing Model Due to a New Software Issue

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026